REHOVOT, Israel and BRIDGEWATER, N.J., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that David Domzalski, President of Foamix Pharmaceuticals, will provide a corporate overview and business update at the Cowen & Company 35th Annual Health Care Conference.
Presentation Details:
Title: | Cowen & Company 35th Annual Health Care Conference |
Date: | Monday, March 2, 2015 |
Time: | 3:30pm Eastern |
Location: | The Boston Marriott Copley Place, Boston, MA |
Webcast: | http://wsw.com/webcast/cowen22/fomx |
About Foamix Pharmaceuticals
We are a clinical-stage specialty pharmaceutical company focused on developing and commercializing our proprietary minocycline foam for the treatment of acne and other skin conditions. Our lead product candidate, FMX101 for moderate-to-severe acne is a topical foam formulation of the antibiotic minocycline. We also have early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.